Evaluation of the polyclonal ELISA HPV serology assay as a biomarker for human papillomavirus exposure

Sarah E. Coseo, Carolina Porras, Lori E. Dodd, Allan Hildesheim, Ana Cecilia Rodriguez, Mark Schiffman, Rolando Herrero, Sholom Wacholder, Paula Gonzalez, Mark E. Sherman, Silvia Jimenez, Diane Solomon, Catherine Bougelet, Leen Jan Van Doorn, Wim Quint, Mahboobeh Safaeian

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: Seropositivity to human papillomavirus (HPV)16 and 18 antibodies is used as a measure of cumulative HPV exposure and as a stratifier of HPV exposure for vaccine efficacy analyses. Overall performance of these assays, as a measure of HPV exposure, has not been evaluated. Methods: Using data from the enrollment phase of the HPV16/18 vaccine trial in Costa Rica, we evaluated the performance of the polyclonal enzyme-linked immunosorbent assay (ELISA) HPV16 and 18 serological assays as a measure of HPV exposure. Biologic (e.g., HPV infection at the cervix) and behavioral characteristics (e.g., lifetime number of sexual partners) with known associations with current and past HPV infection were used to define cases and controls (HPV exposed vs. not exposed). Prevaccination serum was measured for antibodies against HPV16 and 18 by ELISA; cervical samples were tested for HPV DNA using PCR SPF10/LiPA25. ELISA results were analyzed using receiver-operator characteristic curves; performance was evaluated at the manufacturer set cut point (HPV16 = 8, HPV18 = 7) and at cut points chosen to optimize sensitivity and specificity (HPV16 = 34, HPV18 = 60). RESULTS:: Defining cases as type-specific HPV DNA positive with high-grade abnormal cytology (i.e., combined molecular and microscopic markers of infection), HPV16-ELISA gave sensitivity that was lower at the optimal cut point than the manufacturer cut point (62.2 compared with 75.7, respectively; P = 0.44). However, specificity was higher (85.3 compared with 70.4, respectively; P < 0.0001). Similarly, HPV18-ELISA gave sensitivity that was lower at the optimal cut point than the manufacturer cut point (34.5 compared with 51.7, respectively; P = 0.40), with higher specificities (94.9 compared with 72.6, respectively; P < 0.0001). Conclusions: Modifying cut points did not improve the low sensitivity. The low sensitivity of this assay does not support its use for risk stratification or clinical settings.

Original languageEnglish (US)
Pages (from-to)976-982
Number of pages7
JournalSexually Transmitted Diseases
Volume38
Issue number10
DOIs
StatePublished - Oct 2011

Fingerprint

Serology
Biomarkers
Enzyme-Linked Immunosorbent Assay
Papillomavirus Infections
Papillomavirus Vaccines
Costa Rica
Human papillomavirus 18
Human papillomavirus 16
Antibodies
Sexual Partners
DNA
Cervix Uteri
Cell Biology
Vaccines
Sensitivity and Specificity
Polymerase Chain Reaction
Infection
Serum

ASJC Scopus subject areas

  • Dermatology
  • Public Health, Environmental and Occupational Health
  • Microbiology (medical)
  • Infectious Diseases

Cite this

Coseo, S. E., Porras, C., Dodd, L. E., Hildesheim, A., Rodriguez, A. C., Schiffman, M., ... Safaeian, M. (2011). Evaluation of the polyclonal ELISA HPV serology assay as a biomarker for human papillomavirus exposure. Sexually Transmitted Diseases, 38(10), 976-982. https://doi.org/10.1097/OLQ.0b013e31822545c0

Evaluation of the polyclonal ELISA HPV serology assay as a biomarker for human papillomavirus exposure. / Coseo, Sarah E.; Porras, Carolina; Dodd, Lori E.; Hildesheim, Allan; Rodriguez, Ana Cecilia; Schiffman, Mark; Herrero, Rolando; Wacholder, Sholom; Gonzalez, Paula; Sherman, Mark E.; Jimenez, Silvia; Solomon, Diane; Bougelet, Catherine; Van Doorn, Leen Jan; Quint, Wim; Safaeian, Mahboobeh.

In: Sexually Transmitted Diseases, Vol. 38, No. 10, 10.2011, p. 976-982.

Research output: Contribution to journalArticle

Coseo, SE, Porras, C, Dodd, LE, Hildesheim, A, Rodriguez, AC, Schiffman, M, Herrero, R, Wacholder, S, Gonzalez, P, Sherman, ME, Jimenez, S, Solomon, D, Bougelet, C, Van Doorn, LJ, Quint, W & Safaeian, M 2011, 'Evaluation of the polyclonal ELISA HPV serology assay as a biomarker for human papillomavirus exposure', Sexually Transmitted Diseases, vol. 38, no. 10, pp. 976-982. https://doi.org/10.1097/OLQ.0b013e31822545c0
Coseo, Sarah E. ; Porras, Carolina ; Dodd, Lori E. ; Hildesheim, Allan ; Rodriguez, Ana Cecilia ; Schiffman, Mark ; Herrero, Rolando ; Wacholder, Sholom ; Gonzalez, Paula ; Sherman, Mark E. ; Jimenez, Silvia ; Solomon, Diane ; Bougelet, Catherine ; Van Doorn, Leen Jan ; Quint, Wim ; Safaeian, Mahboobeh. / Evaluation of the polyclonal ELISA HPV serology assay as a biomarker for human papillomavirus exposure. In: Sexually Transmitted Diseases. 2011 ; Vol. 38, No. 10. pp. 976-982.
@article{98df909249fb4033bb2facfb3adf38ab,
title = "Evaluation of the polyclonal ELISA HPV serology assay as a biomarker for human papillomavirus exposure",
abstract = "Background: Seropositivity to human papillomavirus (HPV)16 and 18 antibodies is used as a measure of cumulative HPV exposure and as a stratifier of HPV exposure for vaccine efficacy analyses. Overall performance of these assays, as a measure of HPV exposure, has not been evaluated. Methods: Using data from the enrollment phase of the HPV16/18 vaccine trial in Costa Rica, we evaluated the performance of the polyclonal enzyme-linked immunosorbent assay (ELISA) HPV16 and 18 serological assays as a measure of HPV exposure. Biologic (e.g., HPV infection at the cervix) and behavioral characteristics (e.g., lifetime number of sexual partners) with known associations with current and past HPV infection were used to define cases and controls (HPV exposed vs. not exposed). Prevaccination serum was measured for antibodies against HPV16 and 18 by ELISA; cervical samples were tested for HPV DNA using PCR SPF10/LiPA25. ELISA results were analyzed using receiver-operator characteristic curves; performance was evaluated at the manufacturer set cut point (HPV16 = 8, HPV18 = 7) and at cut points chosen to optimize sensitivity and specificity (HPV16 = 34, HPV18 = 60). RESULTS:: Defining cases as type-specific HPV DNA positive with high-grade abnormal cytology (i.e., combined molecular and microscopic markers of infection), HPV16-ELISA gave sensitivity that was lower at the optimal cut point than the manufacturer cut point (62.2 compared with 75.7, respectively; P = 0.44). However, specificity was higher (85.3 compared with 70.4, respectively; P < 0.0001). Similarly, HPV18-ELISA gave sensitivity that was lower at the optimal cut point than the manufacturer cut point (34.5 compared with 51.7, respectively; P = 0.40), with higher specificities (94.9 compared with 72.6, respectively; P < 0.0001). Conclusions: Modifying cut points did not improve the low sensitivity. The low sensitivity of this assay does not support its use for risk stratification or clinical settings.",
author = "Coseo, {Sarah E.} and Carolina Porras and Dodd, {Lori E.} and Allan Hildesheim and Rodriguez, {Ana Cecilia} and Mark Schiffman and Rolando Herrero and Sholom Wacholder and Paula Gonzalez and Sherman, {Mark E.} and Silvia Jimenez and Diane Solomon and Catherine Bougelet and {Van Doorn}, {Leen Jan} and Wim Quint and Mahboobeh Safaeian",
year = "2011",
month = "10",
doi = "10.1097/OLQ.0b013e31822545c0",
language = "English (US)",
volume = "38",
pages = "976--982",
journal = "Sexually Transmitted Diseases",
issn = "0148-5717",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Evaluation of the polyclonal ELISA HPV serology assay as a biomarker for human papillomavirus exposure

AU - Coseo, Sarah E.

AU - Porras, Carolina

AU - Dodd, Lori E.

AU - Hildesheim, Allan

AU - Rodriguez, Ana Cecilia

AU - Schiffman, Mark

AU - Herrero, Rolando

AU - Wacholder, Sholom

AU - Gonzalez, Paula

AU - Sherman, Mark E.

AU - Jimenez, Silvia

AU - Solomon, Diane

AU - Bougelet, Catherine

AU - Van Doorn, Leen Jan

AU - Quint, Wim

AU - Safaeian, Mahboobeh

PY - 2011/10

Y1 - 2011/10

N2 - Background: Seropositivity to human papillomavirus (HPV)16 and 18 antibodies is used as a measure of cumulative HPV exposure and as a stratifier of HPV exposure for vaccine efficacy analyses. Overall performance of these assays, as a measure of HPV exposure, has not been evaluated. Methods: Using data from the enrollment phase of the HPV16/18 vaccine trial in Costa Rica, we evaluated the performance of the polyclonal enzyme-linked immunosorbent assay (ELISA) HPV16 and 18 serological assays as a measure of HPV exposure. Biologic (e.g., HPV infection at the cervix) and behavioral characteristics (e.g., lifetime number of sexual partners) with known associations with current and past HPV infection were used to define cases and controls (HPV exposed vs. not exposed). Prevaccination serum was measured for antibodies against HPV16 and 18 by ELISA; cervical samples were tested for HPV DNA using PCR SPF10/LiPA25. ELISA results were analyzed using receiver-operator characteristic curves; performance was evaluated at the manufacturer set cut point (HPV16 = 8, HPV18 = 7) and at cut points chosen to optimize sensitivity and specificity (HPV16 = 34, HPV18 = 60). RESULTS:: Defining cases as type-specific HPV DNA positive with high-grade abnormal cytology (i.e., combined molecular and microscopic markers of infection), HPV16-ELISA gave sensitivity that was lower at the optimal cut point than the manufacturer cut point (62.2 compared with 75.7, respectively; P = 0.44). However, specificity was higher (85.3 compared with 70.4, respectively; P < 0.0001). Similarly, HPV18-ELISA gave sensitivity that was lower at the optimal cut point than the manufacturer cut point (34.5 compared with 51.7, respectively; P = 0.40), with higher specificities (94.9 compared with 72.6, respectively; P < 0.0001). Conclusions: Modifying cut points did not improve the low sensitivity. The low sensitivity of this assay does not support its use for risk stratification or clinical settings.

AB - Background: Seropositivity to human papillomavirus (HPV)16 and 18 antibodies is used as a measure of cumulative HPV exposure and as a stratifier of HPV exposure for vaccine efficacy analyses. Overall performance of these assays, as a measure of HPV exposure, has not been evaluated. Methods: Using data from the enrollment phase of the HPV16/18 vaccine trial in Costa Rica, we evaluated the performance of the polyclonal enzyme-linked immunosorbent assay (ELISA) HPV16 and 18 serological assays as a measure of HPV exposure. Biologic (e.g., HPV infection at the cervix) and behavioral characteristics (e.g., lifetime number of sexual partners) with known associations with current and past HPV infection were used to define cases and controls (HPV exposed vs. not exposed). Prevaccination serum was measured for antibodies against HPV16 and 18 by ELISA; cervical samples were tested for HPV DNA using PCR SPF10/LiPA25. ELISA results were analyzed using receiver-operator characteristic curves; performance was evaluated at the manufacturer set cut point (HPV16 = 8, HPV18 = 7) and at cut points chosen to optimize sensitivity and specificity (HPV16 = 34, HPV18 = 60). RESULTS:: Defining cases as type-specific HPV DNA positive with high-grade abnormal cytology (i.e., combined molecular and microscopic markers of infection), HPV16-ELISA gave sensitivity that was lower at the optimal cut point than the manufacturer cut point (62.2 compared with 75.7, respectively; P = 0.44). However, specificity was higher (85.3 compared with 70.4, respectively; P < 0.0001). Similarly, HPV18-ELISA gave sensitivity that was lower at the optimal cut point than the manufacturer cut point (34.5 compared with 51.7, respectively; P = 0.40), with higher specificities (94.9 compared with 72.6, respectively; P < 0.0001). Conclusions: Modifying cut points did not improve the low sensitivity. The low sensitivity of this assay does not support its use for risk stratification or clinical settings.

UR - http://www.scopus.com/inward/record.url?scp=80052969420&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052969420&partnerID=8YFLogxK

U2 - 10.1097/OLQ.0b013e31822545c0

DO - 10.1097/OLQ.0b013e31822545c0

M3 - Article

C2 - 21934576

AN - SCOPUS:80052969420

VL - 38

SP - 976

EP - 982

JO - Sexually Transmitted Diseases

JF - Sexually Transmitted Diseases

SN - 0148-5717

IS - 10

ER -